NRx Pharmaceuticals’ (NRXP) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $19.00 price objective on the stock.

NRXP has been the subject of a number of other research reports. D. Boral Capital restated a “buy” rating and issued a $31.00 price objective on shares of NRx Pharmaceuticals in a research report on Tuesday, January 28th. Ascendiant Capital Markets raised their price objective on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, December 2nd.

NRx Pharmaceuticals Stock Performance

Shares of NRXP opened at $2.35 on Friday. NRx Pharmaceuticals has a fifty-two week low of $1.10 and a fifty-two week high of $6.01. The company has a market capitalization of $39.75 million, a price-to-earnings ratio of -1.10 and a beta of 1.22. The firm has a 50-day simple moving average of $3.02 and a 200-day simple moving average of $2.02.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings data on Friday, March 14th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). Equities research analysts forecast that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Insider Activity

In related news, Chairman Jonathan C. Javitt purchased 40,000 shares of NRx Pharmaceuticals stock in a transaction dated Tuesday, December 17th. The stock was bought at an average cost of $1.17 per share, for a total transaction of $46,800.00. Following the transaction, the chairman now owns 84,634 shares in the company, valued at approximately $99,021.78. The trade was a 89.62 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 19.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Sassicaia Capital Advisers LLC purchased a new position in shares of NRx Pharmaceuticals during the 4th quarter worth approximately $33,000. Townsquare Capital LLC purchased a new position in shares of NRx Pharmaceuticals during the 3rd quarter worth approximately $25,000. Squarepoint Ops LLC purchased a new position in shares of NRx Pharmaceuticals during the 4th quarter worth approximately $56,000. Millennium Management LLC purchased a new position in shares of NRx Pharmaceuticals during the 4th quarter worth approximately $61,000. Finally, Anson Funds Management LP increased its stake in shares of NRx Pharmaceuticals by 30.3% during the 4th quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock worth $408,000 after purchasing an additional 43,135 shares in the last quarter. 4.27% of the stock is owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.